erlotinib — CareFirst (Caremark)
Chordoma
Initial criteria
- Member has recurrent conventional or chondroid chordoma
- Erlotinib is used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months